UNSPSC 51202306: Etanercept

This classification denotes an immunosuppressant with the molecular formula C2224H3475N621O698S36, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier OP401G7OJC, more generally known as etanercept. European Medicines Agency schedules etanercept in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01984MIG. The term ETANERCEPT is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 14, No. 1, 2000, list 43.

Most nations, for tariff and trade purposes, schedule Etanercept under HS 30021095 and SITC 54163. SMILES:. As of Q4 2014, ETANERCEPT remains US FDA's Preferred Term for this commodity.. Etanercept bears US NLM identifiers UMLS ID C0717758 and NCI Concept Code C2381.

UNSPSC 51202306 Etanercept is a Commodity code for a specific injectable biologic pharmaceutical used to treat autoimmune conditions; however, recent state and local opportunities posted under this code do not reflect procurement of etanercept itself. Instead, the tagged solicitations center on naloxone (an opioid antagonist), generic multi-source pharmaceuticals and over-the-counter products, and direct-to-manufacturer prescription programs—suggesting either tagging misalignment or that the code's scope has drifted in state and local procurement systems. State and local issuing bodies buying under this nominal code span county health departments, state health and human services agencies, and cooperative purchasing alliances that serve multiple jurisdictions. Seminole County, Florida, and the Texas Health and Human Services Commission represent recent activity, while the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, is soliciting on behalf of participating state and local facilities across multiple states including Oregon.

Geographic activity appears concentrated in Florida, Texas, and Minnesota, with broader multistate reach through the MMCAP cooperative vehicle. Representative recent opportunities include Seminole County's IFB 60459723LAS (posted June 30, 2026; due July 26, 2023) for annual procurement of 1,900 units of naloxone and 800 safe drug deactivation systems with quarterly deliveries; the Texas HHS Commission's RFI HHS0017013 (posted April 3, 2026) exploring direct-to-manufacturer prescription contracting; and MMCAP's RFP S1070000015802 (posted January 20, 2026; due March 26, 2026) for generic multi-source pharmaceuticals and OTC products distributed through three authorized wholesalers with contract effectiveness July 1, 2026. The MMCAP procurement requires cGMP and Drug Supply Chain Security Act compliance, commercial general liability insurance of $5 million per occurrence, and imposes performance penalties up to $1,500 per violation. The gap between the code name (etanercept) and actual procurement activity warrants verification of the code assignment before pursuing opportunities.